Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing

Soo Young Cho, Minhye Choi, Hyo-Jeong Ban, Chang Hyeon Lee, Soojun Park, Han Kyeom Kim, Young‐Sik Kim, Young Seek Lee, Ji-Yun Lee

Oncotarget · 2016 · 36 citations · 32 references

DOIFull text

Open access

Concepts

Abstract

// Soo Young Cho 1, * , Minhye Choi 2, * , Hyo-Jeong Ban 3, 4, * , Chang Hyeon Lee 5 , Soojun Park 6 , HanKyeom Kim 2 , Young-Sik Kim 2 , Young Seek Lee 3 , Ji-Yun Lee 2 1 Laboratory of Developmental Biology and Genomics, College of Veterinary Medicine, Research Institute for Veterinary Science BK21, Program for Veterinary Science, Seoul National University, Seoul 08826, Republic of Korea 2 Department of Pathology, College of Medicine, Korea University, Seoul 02841, Republic of Korea 3 Division of Molecular and Life Sciences, Hanyang University, Ansan 15588, Republic of Korea 4 Division of Bio-Medical Informatics, Center for Genome Science, National Research Institute of Health, Centers for Disease Control and Prevention, Choongchung-Buk-do 28159, Republic of Korea 5 Life Science Solutions Group, Thermo Fisher Scientific Corporation, Seoul 06349, Republic of Korea 6 Bio-Medical IT Research Department, ETRI, Yusoeng-gu, Daejeon 34129, Republic of Korea * These authors have contributed equally to this work Correspondence to: Young Seek Lee, email: yslee@hanyang.ac.kr Ji-Yun Lee, email: jiyun-lee@korea.ac.kr Keywords: cervical small cell neuroendocrine tumor, ATRX, ERBB4, AKT/mTOR, whole exome sequencing Received: July 18, 2016      Accepted: November 22, 2016      Published: December 22, 2016 ABSTRACT Cervical small cell neuroendocrine tumors (CSCNETs) are rare, aggressive neuroendocrine tumors (NETs). Reliable diagnostic and prognostic CSCNET markers are lacking, making diagnosis and prognosis prediction difficult, and treatment strategies limited. Here we provide mutation profiles for five tumor-normal paired CSCNETs using whole exome sequencing (WES). We expanded our assessment of frequently mutated genes to include publicly available data from 55 small intestine neuroendocrine tumors, 10 pancreatic neuroendocrine tumors, 42 small cell lung cancers, six NET cell lines, and 188 cervical cancers, along with our five CSCNETs. We identified 1,968 somatic mutations, including 1,710 missense, 106 nonsense, 144 splice site, 4 lncRNA, 3 nonstop, and 1 start codon mutation. We assigned functions to the 114 most frequently mutated genes based on gene ontology. ATRX , ERBB4 , and genes in the Akt/mTOR pathway were most frequently mutated. Positive cytoplasmic ERBB4 immunohistochemical staining was detected in all CSCNET tumors tested, but not in adjacent normal tissues. To our knowledge, this study is the first to utilize WES in matched CSCNET and normal tissues to identify somatic mutations. Further studies will improve our understanding of how ATRX and ERBB4 mutations and AKT/mTOR signaling promote CSCNET tumorigenesis, and may be leveraged in novel anti-cancer treatment strategies.

References

32